Pepric Appoints Dr. Enrico Bastianelli as Independent Director
News May 27, 2015
The General Assembly of Pepric has appointed Dr. Enrico Bastianelli as independent non-executive Board member. Dr. Bastianelli is the CEO of Bone Therapeutics since 2006, a cell therapy company for bone fracture repair and prevention.
Previously, Dr. Bastianelli gained a tremendous expertise in the cell and pharmaceutical industry based on many years of experience at Procter and Gamble Pharmaceuticals, McKinsey & Co and ProSkelia.
“We are delighted to welcome Dr. Bastianelli to the Board of Pepric, developing instrumentation for cell and particle detection and imaging. His experience and profound understanding of the end-users market of Pepric’s technology will deliver substantial benefit in the decision making process.”, said Stephanie Teughels, CEO of Pepric.
Commenting on his appointment, Dr. Bastianelli said: “I’m pleased to join Pepric offering new solutions for targeted molecular imaging and longitudinal cell detection. I’m looking forward to contribute to its business strategy to maximize the potential of its innovative instruments.”
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE